Literature DB >> 17522340

Donor lymphocyte infusions for the treatment of minimal residual disease in acute leukemia.

Alida Dominietto, Sarah Pozzi, Maurizio Miglino, Flavio Albarracin, Giovanna Piaggio, Francesca Bertolotti, Raffaella Grasso, Simona Zupo, Anna Maria Raiola, Marco Gobbi, Francesco Frassoni, Andrea Bacigalupo.   

Abstract

Entities:  

Mesh：

Year:  2007        PMID： 17522340     DOI： 10.1182/blood-2007-02-072470

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


× No keyword cloud information.
  19 in total

1.  Successful treatment of acute myeloid leukemia co-expressing NUP98/NSD1 and FLT3/ITD with preemptive donor lymphocyte infusions.

Authors:  Yuichi Mitani; Mitsuteru Hiwatari; Masafumi Seki; Mayumi Hangai; Junko Takita
Journal:  Int J Hematol       Date:  2019-05-27       Impact factor: 2.490

2.  Minimal residual disease monitoring and preemptive immunotherapies for frequent 11q23 rearranged acute leukemia after allogeneic hematopoietic stem cell transplantation.

Authors:  Jing Liu; Xiao-Hui Zhang; Lan-Ping Xu; Yu Wang; Chen-Hua Yan; Huan Chen; Yu-Hong Chen; Wei Han; Feng-Rong Wang; Jing-Zhi Wang; Yi-Fei Cheng; Ya-Zhen Qin; Kai-Yan Liu; Xiao-Jun Huang; Xiao-Su Zhao; Xiao-Dong Mo
Journal:  Ann Hematol       Date:  2021-03-13       Impact factor: 3.673

3.  Prophylactic donor lymphocyte infusion after allogeneic stem cell transplantation for high-risk AML.

Authors:  F Legrand; A-C Le Floch; A Granata; S Fürst; C Faucher; C Lemarie; S Harbi; S Bramanti; B Calmels; J El-Cheikh; C Chabannon; P-J Weiller; N Vey; L Castagna; D Blaise; R Devillier
Journal:  Bone Marrow Transplant       Date:  2016-12-12       Impact factor: 5.483

4.  Blinatumomab for Acute Lymphoblastic Leukemia: The First Bispecific T-Cell Engager Antibody to Be Approved by the EMA for Minimal Residual Disease.

Authors:  Sahra Ali; Alexandre Moreau; Daniela Melchiorri; Jorge Camarero; Filip Josephson; Odoardo Olimpier; Jonas Bergh; Dominik Karres; Kyriaki Tzogani; Christian Gisselbrecht; Francesco Pignatti
Journal:  Oncologist       Date:  2019-11-14

Review 5.  Relapse after allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia: an overview of prevention and treatment.

Authors:  Firas Kreidieh; Iman Abou Dalle; Nour Moukalled; Jean El-Cheikh; Eolia Brissot; Mohamed Mohty; Ali Bazarbachi
Journal:  Int J Hematol       Date:  2022-07-16       Impact factor: 2.319

6.  Blinatumomab for Acute Lymphoblastic Leukemia: The First Bispecific T-Cell Engager Antibody to Be Approved by the EMA for Minimal Residual Disease.

Authors:  Sahra Ali; Alexandre Moreau; Daniela Melchiorri; Jorge Camarero; Filip Josephson; Odoardo Olimpier; Jonas Bergh; Dominik Karres; Kyriaki Tzogani; Christian Gisselbrecht; Francesco Pignatti
Journal:  Oncologist       Date:  2019-11-14

7.  Interferon-α Is Effective for Treatment of Minimal Residual Disease in Patients with t(8;21) Acute Myeloid Leukemia After Allogeneic Hematopoietic Stem Cell Transplantation: Results of a Prospective Registry Study.

Authors:  Xiao-Dong Mo; Yu Wang; Xiao-Hui Zhang; Lan-Ping Xu; Chen-Hua Yan; Huan Chen; Yu-Hong Chen; Ya-Zhen Qin; Kai-Yan Liu; Xiao-Jun Huang
Journal:  Oncologist       Date:  2018-08-03

8.  Preemptive low-dose interleukin-2 or DLI for late-onset minimal residual disease in acute leukemia or myelodysplastic syndrome after allogeneic hematopoietic stem cell transplantation.

Authors:  Xiao-Lin Yuan; Ya-Min Tan; Ji-Min Shi; Yan-Min Zhao; Jian Yu; Xiao-Yu Lai; Lu-Xin Yang; He Huang; Yi Luo
Journal:  Ann Hematol       Date:  2020-10-31       Impact factor: 3.673

Review 9.  Relapse of AML after hematopoietic stem cell transplantation: methods of monitoring and preventive strategies. A review from the ALWP of the EBMT.

Authors:  P Tsirigotis; M Byrne; C Schmid; F Baron; F Ciceri; J Esteve; N C Gorin; S Giebel; M Mohty; B N Savani; A Nagler
Journal:  Bone Marrow Transplant       Date:  2016-06-13       Impact factor: 5.483

10.  Good Outcome for Very High Risk Adult B-cell Acute Lymphoblastic Leukaemia Carrying Genetic Abnormalities t(4;11)(q21;q23) or t(9;22)(q34;q11), if Promptly Submitted to Allogeneic Transplantation, after Obtaining a Good Molecular Remission.

Authors:  Matteo Parma; Clara Viganò; Monica Fumagalli; Federica Colnaghi; Arianna Colombo; Federica Mottadelli; Vincenzo Rossi; Elena Elli; Elisabetta Terruzzi; Angelo Belotti; Giovanni Cazzaniga; Enrico Maria Pogliani; Pietro Pioltelli
Journal:  Mediterr J Hematol Infect Dis       Date:  2015-06-01       Impact factor: 2.576
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.